Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1954 1
1955 1
1957 3
1958 1
1965 1
1966 3
1968 3
1969 4
1970 6
1971 4
1972 4
1973 8
1974 5
1975 14
1976 24
1977 24
1978 27
1979 36
1980 41
1981 38
1982 41
1983 44
1984 58
1985 44
1986 51
1987 43
1988 59
1989 65
1990 62
1991 66
1992 61
1993 62
1994 86
1995 79
1996 82
1997 117
1998 103
1999 120
2000 146
2001 134
2002 116
2003 162
2004 168
2005 149
2006 122
2007 112
2008 108
2009 140
2010 145
2011 151
2012 146
2013 113
2014 120
2015 138
2016 139
2017 135
2018 105
2019 99
2020 105
2021 95
2022 92
2023 61
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

4,213 results

Results by year

Filters applied: . Clear all
Page 1
Metastatic and triple-negative breast cancer: challenges and treatment options.
Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. Al-Mahmood S, et al. Drug Deliv Transl Res. 2018 Oct;8(5):1483-1507. doi: 10.1007/s13346-018-0551-3. Drug Deliv Transl Res. 2018. PMID: 29978332 Free PMC article. Review.
Triple negative breast cancer (TNBC) accounts for 10-20% of all cases of breast carcinoma and is characterized by the low expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). ...
Triple negative breast cancer (TNBC) accounts for 10-20% of all cases of breast carcinoma and is characterized by the low expr …
Regional infusion-radioembolization.
Dubel GJ, Soares GM. Dubel GJ, et al. Surg Oncol Clin N Am. 2008 Oct;17(4):957-85, xii. doi: 10.1016/j.soc.2008.04.008. Surg Oncol Clin N Am. 2008. PMID: 18722928 Review.
More than 8000 patients have been treated worldwide, with a large body of experience with primary hepatocellular carcinoma (HCC) and metastatic colorectal carcinoma (MCRC) and growing experience with other tumors (metastatic neuroendocrine, breast carcinoma, cholang …
More than 8000 patients have been treated worldwide, with a large body of experience with primary hepatocellular carcinoma (HCC) and metasta …
Male breast cancer.
Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M, López Gómez M, Casado E. Gómez-Raposo C, et al. Cancer Treat Rev. 2010 Oct;36(6):451-7. doi: 10.1016/j.ctrv.2010.02.002. Epub 2010 Mar 2. Cancer Treat Rev. 2010. PMID: 20193984 Review.
Male breast cancer accounts for around 1% of all breast cancer cases, but the incidence has increased over the past 25 years. The rarity of this entity precludes prospective randomized clinical trials. Although breast carcinoma in both genders share ce …
Male breast cancer accounts for around 1% of all breast cancer cases, but the incidence has increased over the past 25 years. The rarity of …
Trastuzumab-associated cardiotoxicity.
Keefe DL. Keefe DL. Cancer. 2002 Oct 1;95(7):1592-600. doi: 10.1002/cncr.10854. Cancer. 2002. PMID: 12237930 Free article. Review.
Trastuzumab is a monoclonal antibody used for the treatment of metastatic breast carcinoma in women whose tumors overexpress the HER2 protein. ...
Trastuzumab is a monoclonal antibody used for the treatment of metastatic breast carcinoma in women whose tumors overexpress t …
Diagnosis and Management of High-Risk Breast Lesions.
Thomas PS. Thomas PS. J Natl Compr Canc Netw. 2018 Nov;16(11):1391-1396. doi: 10.6004/jnccn.2018.7099. J Natl Compr Canc Netw. 2018. PMID: 30442737 Review.
This review explores the studies evaluating the risk for breast cancer in women with AH or LCIS and the clinical management of these lesions, which can include a combination of surgical excision, surveillance, and risk-reduction therapy....
This review explores the studies evaluating the risk for breast cancer in women with AH or LCIS and the clinical management of these …
Novel applications of proton therapy in breast carcinoma.
Cuaron JJ, MacDonald SM, Cahlon O. Cuaron JJ, et al. Chin Clin Oncol. 2016 Aug;5(4):52. doi: 10.21037/cco.2016.06.04. Chin Clin Oncol. 2016. PMID: 27558253 Free PMC article. Review.
This review will focus on the indications, clinical experience, and technical considerations of proton beam radiation therapy in the treatment of patients with breast cancer. ...For patients with locally advanced breast cancer requiring treatment to the regional lymph node …
This review will focus on the indications, clinical experience, and technical considerations of proton beam radiation therapy in the …
Clinical Trials for Ductal Carcinoma In Situ of the Breast.
Han MS, Khan SA. Han MS, et al. J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):293-301. doi: 10.1007/s10911-018-9413-3. Epub 2018 Sep 11. J Mammary Gland Biol Neoplasia. 2018. PMID: 30206737 Review.
Ductal carcinoma in situ (DCIS) of the breast is a non-obligatory precursor to invasive breast carcinoma, with a variable natural history and biological potential for progression to invasive disease. ...This review summaries the major past and current clinical …
Ductal carcinoma in situ (DCIS) of the breast is a non-obligatory precursor to invasive breast carcinoma, with a variable natu …
Bisphosphonates and breast carcinoma.
Lipton A. Lipton A. Cancer. 1997 Oct 15;80(8 Suppl):1668-73. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1668::aid-cncr17>3.3.co;2-5. Cancer. 1997. PMID: 9362434 Review.
The skeleton is a common site of breast carcinoma metastasis; 75% of patients with breast carcinoma demonstrate bone metastases at autopsy. ...Phase II studies again suggested an improvement in many of the skeletal complications of breast car …
The skeleton is a common site of breast carcinoma metastasis; 75% of patients with breast carcinoma demonstrate …
The interplay of endocrine therapy, steroid pathways and therapeutic resistance: Importance of androgen in breast carcinoma.
Takagi K, Miki Y, Ishida T, Sasano H, Suzuki T. Takagi K, et al. Mol Cell Endocrinol. 2018 May 5;466:31-37. doi: 10.1016/j.mce.2017.09.011. Epub 2017 Sep 13. Mol Cell Endocrinol. 2018. PMID: 28918115 Review.
In addition, treatment for the patients with triple-negative breast carcinomas (negative for all ER, progesterone receptor (PR) and HER2) are limited to cytotoxic chemotherapy and novel therapeutic targets need to be identified. In breast carcinoma tissues, not only …
In addition, treatment for the patients with triple-negative breast carcinomas (negative for all ER, progesterone receptor (PR) and HER2) ar …
Non-invasive breast carcinoma.
Posner MC, Wolmark N. Posner MC, et al. Breast Cancer Res Treat. 1992;21(3):155-64. doi: 10.1007/BF01974998. Breast Cancer Res Treat. 1992. PMID: 1325215 Review.
Non-invasive breast cancer is comprised of two distinct entities: lobular carcinoma in-situ (LCIS) and ductal carcinoma in-situ (DCIS). The natural history of each clinical entity is described and a biologic interpretation of the available data is offered. ...The pitfalls …
Non-invasive breast cancer is comprised of two distinct entities: lobular carcinoma in-situ (LCIS) and ductal carcinoma in-situ (DCIS). The …
4,213 results